miRNA Modulation for HER2-Dependent Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HER2-dependent cancers, such as HER2+ breast cancer, face limitations due to resistance issues and toxicity concerns with existing therapies, necessitating the development of alternative approaches that can effectively target HER2 without inducing significant side effects.
Innovation Solution
Modulating the activity of specific micro ribonucleic acids (miRNAs), including miRNA 429-3p, miR29c-3p, and miR200b-3p, to reduce HER2 activation, offering a new therapeutic strategy that differs from traditional therapies like Trastuzumab and Lapatinib, and can block activation in Trastuzumab-resistant cell lines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-HER2 antibody therapies (Trastuzumab) are used to target HER2, then HER2 activation is inhibited, but therapeutic resistance develops due to p95HER-2 expression
Solution Approach 1:
The patent uses RNA interference (RNAi) technology as an intermediary mechanism to target HER2 mRNA at the transcriptional level, bypassing the need to bind to the protein structure that p95HER-2 lacks. This intermediary approach (using small interfering RNAs) allows inhibition of both full-length HER2 and truncated p95HER-2 forms that share common mRNA sequences, thereby overcoming the resistance problem associated with antibody therapies.
Solution Approach 2:
The patent replaces the mechanical binding mechanism of antibodies (which require specific epitopes on the protein surface) with a molecular recognition system based on nucleic acid complementarity. This substitution allows targeting of the mRNA template rather than the folded protein, enabling inhibition of HER2 expression at a level where the distinction between full-length and truncated forms is less critical.
2Reliability
If small molecule tyrosine kinase inhibitors (Lapatinib) are used to inhibit HER2 kinase activity, then HER2 signaling is blocked, but non-specific inhibition of other kinases causes increased toxicity
Solution Approach 1:
The patent applies local quality by designing RNAi molecules with specific sequence complementarity that targets only HER2 mRNA. This localized molecular recognition ensures that only the intended target (HER2) is inhibited, while other kinases remain unaffected, thereby eliminating the non-specific toxicity associated with broad-spectrum kinase inhibitors.
Solution Approach 2:
The patent changes the molecular parameter of target recognition from protein-based (kinase active site binding) to nucleic acid-based (mRNA sequence complementarity). This parameter change allows for highly specific targeting of HER2 mRNA without affecting other kinases, thus reducing off-target toxicity while maintaining efficacy.
3Reliability
If traditional HER2-targeting therapies are used, then HER2 activation is reduced, but the duration of response is limited to less than one year
Solution Approach 1:
The patent employs preliminary action by using RNAi to suppress HER2 mRNA expression before the cancer can develop resistance mechanisms. By preventing the accumulation of HER2 protein at the transcriptional level, the therapy proactively blocks the initiation of resistance pathways that typically develop during prolonged exposure to protein-targeting therapies.
Solution Approach 2:
The patent ensures continuity of useful action through the sustained suppression of HER2 mRNA expression. RNA interference provides continuous inhibition of HER2 protein synthesis as long as the therapeutic agent is present, preventing intermittent expression that could allow resistance to develop and maintaining consistent therapeutic pressure on the cancer cells.
Data Source
AI summary
This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.